Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
627 clinical trials found
Clinical trials

MK-1022-011

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers (NCT06596694)

Currently recruiting

MK-1200-002

A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors (NCT06242691)

No longer recruiting

MK-4280A-010

A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (NCT06036836)

No longer recruiting

MK-6837

A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors (NCT06460961)

Currently recruiting

MK-8591B 060

Phase 2 Study of ISL+ULO QW in Virologically Suppressed Adults With HIV-1 (NCT06891066)

Currently recruiting

MK1022-016

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physicians Choice in Hormone Receptorpositive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer [HERTHENA-Breast04] (NCT07060807)

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread. HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2. Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles. Metastatic means the cancer has spread to other parts of the body. Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.
Coming soon

MK7240-012

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderate to Severe Hidradenitis Suppurativa (NCT06956235)

This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. This study consists of a 16-week Double-blind Period and a 100-week Longterm Extension (LTE) composed of a 40-week Main Extension and a 60-week Optional Extension. Each participant will participate in the study for approximately 135 weeks from the time the participant provides documented informed consent through the final contact. (including screening & follow up). There will be 147 participants across 70 centers worldwide.
No longer recruiting

MKC-CI-002

ICoN-1: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101 [Clofazimine Inhalation Suspension] When Added to Guideline-Based Therapy in Participants with Pulmonary Nontuberculous Mycobacterial Infection [Part A] Followed by an Open-Label Extension [Part B] (NCT06418711).

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT).
Currently recruiting

MND-PLL001

A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo-controlled Study with an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001 for the Treatment of Subjects with Amyotrophic Lateral Sclerosis (NCT06513546)

Currently recruiting

MOG001

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) (NCT05063162)

Currently recruiting

MonumenTAL-2

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma (NCT05050097)

Currently recruiting

MonumenTAL-8

A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma (MonumenTAL-8) (NCT06550895)

Currently recruiting

MRDRIVE-ALL

MRDRIVE-ALL: Minimal Residual Disease Driven Intervention in Elderly Acute Lymphoblastic Leukaemia (Trial Not Registered)

Currently recruiting

mRNA-2752

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade (NCT03739931)

No longer recruiting

MRTLE-DB

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 via an Implantable Pump and a Cranial Port and Double Lumen Catheter (CIC) in Subjects with Focal Seizures, with Temporal Lobe Onset with or without Secondary Generalization (NCT04153175)

Currently recruiting

MRTLE-OLE

An Open-Label Extension Study to Investigate the Long-Term Safety, and Tolerability of Intracerebroventricular (ICV) Delivery of Valproate in Subjects with Focal Seizures, with Temporal Lobe Onset with or without Secondary Generalization (NCT04529954)

Currently recruiting

MTX-GPC3-303

A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT 303 in Adults with Advanced or Metastatic GPC3-Expressing Cancers, including Hepatocellular Carcinoma (NCT06478693)

Currently recruiting

Multisite

Inter-organ cross talk in heart failure: A multisite biomarker sampling study (ACTRN12621001725853)

Non fasting blood samples are collected during the patients clinically indicated right heart catheterisation procedure. Blood is taken from the coronary sinus, pulmonary, hepatic and renal vein and from an arterial site. An echocardiogram is performed if the patient has not had one within the past 3 months. A 6 WMT and QOL questionnaires, ECG may also be performed.
Currently recruiting

MY-PROMPT-2

More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures – MY-PROMPT-2 (TRU-MP2-22/AMaRC 22-02) (ACTRN12622001199707p)

Currently recruiting

NADINA

Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma - NADINA (NCT04949113)

No longer recruiting
19 20 21 22 23